BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Apple Turns 50: From Garage Startup to AI Crossroads 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
NEW YORK, Dec. 01, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Osiris Therapeutics, Inc. (NASDAQ:OSIR) securities between May 12, 2014 and November 20, 2015.
Click here to learn about the case: http://docs.wongesq.com/OSIR-Info-Request-Form-1014. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Osiris improperly recognized revenue under contracts it had with its distributors; (2) Osiris’ disclosure controls and procedures were not effective as of December 31, 2014, March 31, 2015, and June 30, 2015; and (3) as a result, defendants’ statements about Osiris’ business and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Osiris Therapeutics you have until January 22, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/OSIR-Info-Request-Form-1014.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
